SPOTLIGHT: Drug makers delaying generics
With lawmakers poised to consider new legislation on generic drugs, the FTC has concluded that the drug industry is increasingly paying generic drugmakers to stop them from rolling out cheap knockoffs. Half of the 28 patent litigation settlements struck in the year leading up to Sept. 30 included such a pact. The Senate Judiciary Committee has begun an investigation into the payments, which two appeals court decisions concluded were legal in 2005. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
